June 10, 2025 09:06 PM EDTUpdated 09:41 PM
People
Pharma
Cell/Gene Tx

Ver­tex lays off 125 work­ers af­ter type 1 di­a­betes cell ther­a­py failed study in March

Kyle LaHucik

Biotech Correspondent

Ver­tex Phar­ma­ceu­ti­cals is let­ting go of 125 em­ploy­ees in Rhode Is­land af­ter a clin­i­cal dis­ap­point­ment for its Phase 1/2 type 1 di­a­betes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

Up­dat­ed: A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

Com­pass claims Phase 3 win in de­pres­sion for psilo­cy­bin drug, moves clos­er to FDA fil­ing

Ver­tex's di­a­betes cell ther­a­py al­lows 10 pa­tients to come off in­sulin

Phar­ma com­pa­nies are weigh­ing how a drug’s IP lo­ca­tion could im­pact tar­iffs

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times